Why the study?
Does the ET(A) receptor antagonist BQ-123 increase forearm blood flow in healthy volunteers?
Does the ET(A) receptor antagonist BQ-123 increase forearm blood flow in healthy volunteers?
Intra-arterial infusion of low-dose BQ-123 (50 nmol/min) significantly increases forearm blood flow, confirming the role of basal endothelin-1 in regulating vascular tone.
Supports basal ET-1 regulation of vascular tone in humans; leaves open therapeutic translation pending clinical trials.
AIMS: Endothelin-1 is a potent endogenous vasoconstrictor that acts on the endothelin A (ET[A]) receptor. The dose-response and time-course of the dilator effect of the ET(A) receptor antagonist, BQ-123, was investigated in the forearm of healthy volunteers. METHODS: Forearm blood flow was measured using mercury-in rubber strain gauge venous occlusion plethysmography. RESULTS: Following intra-arterial infusion of BQ-123 (50 nmol min-1) for 5 min, forearm blood flow increased by approximately 60% over the next 60 minutes; lower doses were without significant effect. The degree of dilatation was similar to that observed in previous studies using 20-fold larger doses. CONCLUSIONS: This study confirms that basal endothelin-1 has a role in the physiological regulation of vascular tone. It is possible that at low doses, BQ-123 might be a more sensitive pharmacological tool for the detection of abnormal endothelin-1 mediated constriction.
No takes yet. Share an insight, caveat, or question.
Berrazueta et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: